Accuray – ARAY – Signs Master Research and Collaboration Agreement With University of Heidelberg

Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city’s top international position in therapy, research and science. ARAY and the University of Heidelberg will collaborate on cutting-edge research in radiation oncology to advance treatment technology and provide health care professionals with the most advanced tools for treating patients.

A longstanding research collaboration with the University of Heidelberg has been in existence surrounding TomoTherapy technology, which included exploration of new treatment options with helical TomoTherapy and associated journal publications about advanced use of this expanded application. The University of Heidelberg was the first TomoTherapy installation in Germany in 2006. A second TomoTherapy System was installed in 2010. Together these systems – a TomoHD and a TomoTherapy Hi-Art – treat approximately 700 patients per year, representing 70 percent of the approximately 1,000 patients treated by intensity modulated radiation therapy (IMRT) at the hospital each year, and 20 percent of the approximately 3,500 patients treated by their Radiation Oncology department each year.

“We are pleased to be partnering with Accuray to advance cancer care,” said Prof. Dr. Dr. Jurgen Debus, Director of the Department of Radiation Oncology, University of Heidelberg. “We have a long history using TomoTherapy technologies and have seen the benefits they offer cancer patients, so we are eager to explore further scientific advancements together.”

“We are extremely pleased to be entering into this important research and collaboration agreement with the University of Heidelberg, as we work together to explore new paradigms in radiation oncology for the betterment of patient care,” said Euan S. Thomson, Ph.D., Accuray president and chief executive officer. “As the premier radiation oncology company with market-leading technologies for image-guided IMRT and radiosurgery, we believe partnerships such as this can make huge inroads in advancing treatment technologies and improving patient care.”

About ARAY
ARAY, based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 300,000 patients worldwide have been treated using the Company’s technologies and more than 616 systems have been installed in leading hospitals around the world.

More Posts by this author

• 
  Gold Prices Edge Higher
• 
  Stocks End on a Mixed Note; Dow Jones, S&P 500 Post Best Quarterly Performance Since 1998
• 
  Stocks Headed for a Higher Finish
• 
  Tibco Software Shares Slip after Q1 Results (TIBX)
• 
  Gold and Silver Prices Hold on to Gains
• 
  Stocks Higher in Mid-Day Trading
• 
  Stocks Marginally Higher

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.